Innovative Collaboration to Enhance Gene Therapy Manufacturing
eXmoor pharma, a prominent cell and gene therapy manufacturing partner, along with Virica Biotech Inc., a leader in enhancers for scaling viral vectors, has embarked on a groundbreaking project. This initiative has garnered funding through a collaborative biomanufacturing effort involving the Canada-UK governments. The goal is to optimize the manufacturing process of adeno-associated vectors (AAVs), which are essential for effective gene therapies.
The Importance of AAVs in Gene Therapies
Gene therapies have a powerful impact, often requiring just a single dose to treat or even cure challenging health conditions. However, their production is fraught with difficulties, particularly due to their high manufacturing costs. The industry is challenged by the necessity of specialized processes and the complexities of expanding production. Specifically, growing AAVs in HEK293 cells presents unique hurdles that must be addressed to make these therapies more broadly available.
Virica’s Groundbreaking VSE Technology
Virica’s Viral Sensitizer Enhancers (VSEs™) were developed using their innovative High Throughput Virology Platform. This technology includes small molecules designed to enhance cellular responses in the manufacturing process. By fine-tuning the innate immune responses of HEK293 cells, which typically hinder AAV replication, Virica aims to boost AAV production. The partnership with eXmoor allows for the application of these VSE formulations across various scales, from small lab batches to large-scale commercial production.
Leadership Insights on the Partnership
Angela Osborne, CEO of eXmoor, expressed gratitude for the support from Innovate UK, emphasizing the project’s potential impact on the industry and patients alike. She stated, “Together, Virica and eXmoor aim to produce validated VSE™ enhancer formulations that our clients and global manufacturing partners can utilize.” This sentiment highlights the collaborative spirit and the shared vision of advancing healthcare solutions.
Vision for Improved Efficiency
Virica’s co-founder and CEO, Jean-Simon Diallo, added that the partnership and financial backing from the National Research Council of Canada Industrial Research Assistance Program represent a significant commercial opportunity. He noted, “The advisory services and funding will help us enhance the production efficiency of life-saving therapies.” The collaboration marks an exciting step towards fostering strong ties between Canada and the UK, paving the way for future advancements in biotechnology.
Supporting Research and Development in Biomanufacturing
The funding secured through the Canada-UK Biomanufacturing of Biologics and Advanced Therapies program provides essential resources to support this innovative project. Both eXmoor pharma and Virica will leverage this financial and advisory support to expedite their respective contributions, pushing the boundaries of what is possible in gene therapy manufacturing.
About eXmoor pharma
As a prominent player in the biotechnology sector, eXmoor pharma has established itself as a reliable partner in cell and gene therapy manufacturing. Founded in 2004, with a specialized focus since 2007, eXmoor supports organizations in developing robust CMC strategies. Their combination of GMP manufacturing capabilities and comprehensive consulting services has led to the successful completion of over 500 projects across various clients.
About Virica Biotech
Virica Biotech specializes in developing enhancers that streamline the production of viral vectors and cell and gene therapies. By improving manufacturing efficiency and reducing costs, Virica's VSE™ platform aims to support the industry in scaling their therapeutic products effectively. Their targeted VSE™ formulations enhance yields while making the production of vital therapies more cost-effective.
Frequently Asked Questions
What is the main goal of the collaboration between eXmoor and Virica?
The collaboration aims to improve the manufacturing process of adeno-associated vectors (AAVs), crucial for effective gene therapies, by leveraging Virica’s VSE technology.
How does the VSE technology enhance AAV production?
VSE technology augments the innate cellular responses of HEK293 cells, which helps in overcoming barriers that impede AAV replication and boosts production efficiency.
What support did eXmoor and Virica receive for their project?
The project received funding and advisory services through the Canada-UK biomanufacturing initiative, which enhances the potential outcomes of their collaboration.
What has been the impact of eXmoor pharma in the industry?
eXmoor pharma has completed over 500 projects, becoming a valuable partner for organizations looking to navigate the complexities of cell and gene therapy manufacturing.
How does this project benefit patients?
By improving the manufacturing processes of gene therapies, the collaboration aims to reduce costs and make these crucial treatments more accessible to patients in need.
